Compass Therapeutics resumed with an Outperform at Raymond James

Raymond James analyst Sean McCutcheon resumed coverage of Compass Therapeutics (CMPX) with an Outperform rating and $9 price target Tovecimig has demonstrated superiority on response rate to its comparator arm in the Phase 3 COMPANION-002 study, notes the analyst, who believes it will hit statistical significance on progression-free survival with a U.S. approval in second-line biliary tract cancer during 2026. Should Tovecimig get approved, the firm thinks the launch of the drug will be “strong given the low bar” and lack of efficacy for standard chemotherapy regimens in the roughly 60% of second-line BTC patients without targetable genomic alterations, the analyst added.